Vibegron
Brand name: Gemtesa
Rank #98 of 500 drugs by total cost
$185.2M
Total Cost
283,953
Total Claims
$185.2M
Total Cost
5,567
Prescribers
$652
Cost per Claim
57,107
Beneficiaries
410,009
30-Day Fills
$33K
Avg Cost/Provider
51
Avg Claims/Provider
About Vibegron
Vibegron (sold as Gemtesa) was prescribed 283,953 times by 5,567 Medicare Part D providers in 2023, costing the program $185.2M. At $652 per claim, this is a high-cost medication.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 95 | Darolutamide (Nubeqa) | $188.8M | 14,375 |
| 96 | Fluticasone Propionate (Fluticasone Propionate) | $187.5M | 5,343,836 |
| 97 | Hydrocodone/Acetaminophen (Hydrocodone-Acetaminophen) | $185.6M | 8,496,609 |
| 98 | Vibegron (Gemtesa) | $185.2M | 283,953 |
| 99 | Omeprazole (Omeprazole) | $182.7M | 12,147,266 |
| 100 | Amlodipine Besylate (Amlodipine Besylate) | $180.1M | 20,835,727 |
| 101 | Dolutegravir Sodium/Lamivudine (Dovato) | $173.3M | 56,930 |
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology